Clinical trial
A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM)
NCT05271240 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized Trial of Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab (Avastin) With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed Glioblastoma (GBM)
- Lead sponsor
- Northwell Health
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- April 27, 2022
- Completion date
- April 1, 2028
- Enrollment
- 432 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
brain cancer, gbm, glioblastoma, glioblastoma multiforme, glioblastoma multiforme, adult, glioblastoma, idh-wildtype, glioma, malignant